製藥和生物技術產業的權利金比率：2015-2026年

根據醫藥和生物技術領域的實際授權協議確定權利金比率。

在醫藥和生技領域的授權協議中，合理的權利金比率是多少？此外，在談判過程中應該使用哪些理由來支持此費率水準？

本報告分析了超過 1640 筆產生版稅的許可交易，以提供基於證據的資訊來回答這些問題。

本報告目的是為業務發展、許可、估值、法律、策略和高階主管角色提供服務，使能夠將提案權使用費條款與類似的實際交易進行比較，並根據交易的整體經濟狀況、權利結構和所涉資產的發展階段來評估權利金。

目標不僅是確定權利金比率，而是要了解該權利金率是否合理，與相關的市場先例相比處於什麼位置，以及它如何融入交易的整體經濟條件。

相似交易：辨識最重要的交易

只有當基礎交易真正具有可比性時，權利金比率才能作為基準。

本報告有助於確定與評估的資產、技術和交易更密切相關的授權交易，而不是依賴行業平均水準或單一的公開披露的權利金比率。

類似交易可根據以下因素進行評估：

• 發展階段
• 治療區域
• 技術類型
• 公司
• 交易類型
• 目標區域
• 獨家版權
• 預付款
• 里程碑結構
• 整個交易的經濟效益
• 這樣一來，業務發展、授權、估值和策略團隊就可以建立更相關的交易範例集，並評估提案的權利金條款是否現實、合理且符合市場慣例。
• 對於準備談判、公司估值或內部交易審查的團隊來說，類似交易的例子可以為支持假設、檢驗所提供的條款以及了解類似交易中實際達成一致的範圍提供更強力的基礎。
• 通用AI工具無法取代它的原因
• 雖然通用AI工具搜尋和匯總公開資訊，但它們無法存取 Current Partnering 專有的、由分析師精心整理的權利金比率資料集或其類似許可交易的結構化資料庫。

目前的合作模式提供以下幾種組合：

• 包括權利金的醫藥和生物技術領域的1,640 項授權交易。
• 超過 540 項基礎授權協議
• 依研發階段、治療領域、技術、公司和交易類型進行系統分析。
• 詳細的財務條款，包括版稅、預付款、里程碑付款和交易總額。
• 對獨家經營權、區域權利和交易結構的分析
• 分析師挑選並彙總了生命科學領域授權和業務發展的類似交易資訊。
• AI搜尋可協助找到單一報導並彙總已知的交易詳情。本報告提供結構化的證據基礎，用於識別真正可比較的交易、在特定背景下對權利金比率進行基準測試，並仔細審查數百份實際許可協議背後的合約條款。
• Current Partnering 提供必要的證據、系統資訊和專家解讀，以支持實際的許可決定。

目錄

執行摘要

第1章 引言

• 什麼是忠誠？
• 權利金比率歷史
• 製藥和生物技術領域的權利金
• 版稅與收益分成
• 報告摘要

第2章 醫藥和生技領域的權利金比率：概述

• 權利金比率趨勢
• 利潤分成金額是如何計算的？
• 近期文獻綜述
• 未來權利金比率

第3章 醫藥和生技交易中的權利金條款

• 合夥協議的結構
• 權利金條款的典型結構
• 版稅條款範例
  • 案例研究1
  • 案例研究2
  • 案例研究3
  • 案例研究4

第4章 主動揭露權利金比率的公司

• 最積極揭露權利金比率的公司

第5章 版權利金比率合約目錄

• 查看交易協議中規定的權利金比率，以獲取更詳細的資訊。
• 交易目錄
• 交易目錄：權利金比率：依公司（A-Z）
• 交易目錄：權利金比率：依治療領域分類
• 交易目錄：權利金比率：依合約簽訂時的開發階段分類
• 交易目錄：權利金比率：依技術類型分類
• 權利金比率參考資料
• 包含權利金比率的交易協議範例
• 關於 Biopharma Research Ltd.
• Current Partnering
• Current Agreements
• Current Partnering近期報告標題

Benchmark Royalty Rates Against Real-World Pharmaceutical and Biotechnology Licensing Deals

What is a realistic royalty rate for a pharmaceutical or biotechnology licensing deal - and what evidence can you use to support that rate in a negotiation?

Royalty Rates in Pharmaceutical and Biotechnology Licensing Deals provides an evidence-based resource for answering these questions, drawing on more than 1,640 royalty-bearing licensing transactions.

Designed for business development, licensing, valuation, legal, strategy and executive teams, the report enables users to benchmark proposed royalty terms against real-world comparable transactions and evaluate royalties in the context of the wider deal economics, rights structure and development profile of the asset.

The objective is not simply to identify a royalty percentage; it is to understand whether that royalty is realistic, how it compares with relevant market precedents, and how it fits within the complete economics of the transaction.

Comparable Transactions: Find the Deals That Matter Most

A royalty rate is only useful as a benchmark if the underlying transaction is genuinely comparable.

The report helps users identify licensing deals that more closely match the asset, technology or transaction they are evaluating, rather than relying on broad industry averages or isolated headline royalty figures.

Comparable transactions can be assessed according to factors including:

• Development stage
• Therapeutic area
• Technology type
• Company
• Deal type
• Territorial scope
• Exclusivity
• Upfront payments
• Milestone structures
• Overall deal economics
• This enables business development, licensing, valuation and strategy teams to build a more relevant set of transaction precedents and assess whether proposed royalty terms are realistic, defensible and consistent with market practice.
• For teams preparing for a negotiation, valuation or internal deal review, this comparable-deal evidence provides a stronger basis for supporting assumptions, challenging proposed terms and identifying the range within which similar transactions have actually been agreed.
• Why Generic AI Is Not a Substitute for This Intelligence
• Generic AI tools can search and summarise publicly available information. They do not provide access to Current Partnering's proprietary, analyst-curated royalty rate dataset or its structured body of comparable licensing transactions.

Current Partnering combines:

• 1,640 royalty-bearing pharmaceutical and biotechnology licensing deals
• 540+ underlying licensing agreements
• Structured analysis by development stage, therapeutic area, technology, company and deal type
• Detailed financial terms including royalties, upfront payments, milestones and total deal value
• Analysis of exclusivity, territorial rights and transaction structure
• Analyst-curated comparable transaction intelligence built specifically for life sciences licensing and business development
• An AI search may help locate an individual announcement or summarise a known transaction. This report provides the structured evidence base needed to identify genuinely comparable deals, benchmark royalty rates in context and examine the contractual terms behind hundreds of real licensing agreements.
• Current Partnering provides the evidence, structure and expert interpretation needed to support a real licensing decision.
• Reasons to Buy
• Benchmark royalty rates against 1,640 real pharmaceutical and biotechnology licensing deals to establish a stronger evidence base for valuation and negotiation
• Identify genuinely comparable transactions by development stage, therapeutic area, technology, company and deal structure rather than relying on broad industry averages
• Review 540+ underlying licensing agreements to examine how royalty clauses and related commercial terms are structured in real-world transactions
• Assess whether proposed royalty terms are commercially realistic and defensible by comparing royalty rates, ranges, tiered structures and associated payment terms in similar deals
• Understand the complete economics behind the royalty rate, including how royalties interact with upfront payments, milestones, exclusivity and territorial rights
• Strengthen licensing negotiations, valuations and internal deal approvals with objective comparable-transaction evidence
• Qualifying purchasers may receive a complimentary tailored Current Partnering Executive Briefing, applying the report's evidence to their own asset, technology, platform or partnering priorities
• Key Questions Answered

The report can help users answer commercially important questions including:

• What royalty rates have been agreed in genuinely comparable pharmaceutical and biotechnology licensing deals?
• What royalty range may be realistic and defensible for an asset at a particular development stage?
• How do royalty rates vary by therapeutic area, technology and stage of development?
• How do royalty rates interact with upfront payments, milestones, exclusivity and territorial rights?
• When are tiered, escalating or variable royalty structures used, and how are they structured?
• Which comparable transactions provide the strongest evidence for a valuation, negotiation position or internal deal approval?
• What the Report Includes
• This latest edition covers 1,640 royalty-bearing pharmaceutical and biotechnology licensing transactions.

Coverage includes:

• 1,640 royalty-bearing licensing transactions
• Royalty rate benchmarking by development stage, therapeutic area, technology, company and deal type
• Tiered royalties, escalators and royalty ranges where disclosed
• Supporting financial terms including upfront payments, milestones and total deal value
• Analysis of exclusivity, territorial rights and overall transaction structure
• 540+ underlying licensing agreements, including royalty clauses and contractual terms
• Royalty rate trends
• Structured comparable-deal directories for identifying relevant transaction precedents
• Access Real Licensing Agreements and Royalty Clauses
• Royalty terms can be difficult to research because headline announcements often provide only limited information on the detailed economics of a transaction.
• The dataset provides access to underlying licensing agreements, enabling users to move beyond headline deal announcements and examine how royalty and other commercial provisions are actually structured in real transactions.

These agreements can provide insight into areas including:

• Royalty percentages and ranges
• Tiered royalty structures
• Sales thresholds
• Royalty escalation and reduction mechanisms
• Royalty duration
• Territory
• Exclusivity
• Sublicensing provisions
• Milestone structures
• Other financial and commercial terms
• For business development, licensing and legal teams, this provides an opportunity to examine actual contract language and transaction mechanics, rather than relying solely on publicly announced headline terms.
• Built for Real-World Licensing Decisions and Valuation
• The report is designed to support real licensing decisions - from initial valuation and comparable deal analysis through negotiation and internal transaction approval.
• Business development and licensing teams can identify comparable transactions, benchmark proposed terms and prepare evidence for partner negotiations.
• Valuation and finance teams can use real-world transaction evidence to test royalty assumptions in asset valuations, financial models and forecasts.
• Legal and transaction teams can examine how royalty provisions and related commercial terms are structured in actual agreements.
• Executive and investment committees can use comparable transaction evidence to pressure-test assumptions before approving proposed licensing transactions.
• Consultants, advisers and investors can use the intelligence to support valuation, transaction analysis, due diligence and client engagements.
• Save Significant Research Time Without Sacrificing Evidence Quality
• Reliable royalty rate information is fragmented across press releases, regulatory filings, financial disclosures, investor materials and licensing agreements.
• Finding an individual royalty figure may be relatively straightforward. Building a sufficiently large, structured and genuinely comparable group of transactions to support a valuation or negotiation is a very different research task.
• Current Partnering has already consolidated and classified royalty-bearing transactions, financial terms and underlying contracts so users can move directly to identifying and assessing the evidence most relevant to their deal.
• This enables teams to spend less time assembling fragmented transaction information and more time interpreting the evidence, testing assumptions and preparing for the commercial decision itself.
• Complimentary Tailored Executive Briefing for Qualifying Purchasers
• Qualifying purchasers may also receive a complimentary Current Partnering Executive Briefing tailored to their specific technology, product, asset, platform, pipeline or partnering priorities.

Drawing on Current Partnering's proprietary deal intelligence, the briefing can identify:

• Relevant comparable transactions
• Royalty rate benchmarks
• Comparable deal structures
• Financial benchmarks
• Potential partners and active dealmakers
• Market and transaction trends relevant to the purchaser's objectives
• Practical observations to support valuation, licensing strategy and negotiation planning
• The published report provides the market evidence; the tailored briefing helps show how that evidence applies to the purchaser's own commercial situation.
• Qualifying purchasers are typically pharmaceutical, biotechnology or other life sciences companies with an identifiable product, technology, asset, platform or partnering objective that can be meaningfully benchmarked against Current Partnering's deal intelligence.

Table of Contents

Executive Summary

Chapter 1 - Introduction

• 1.1. What are royalties?
• 1.2. History of royalty rates
• 1.3. Royalties in pharmaceuticals and biotechnology
• 1.4. Royalties versus revenue share
• 1.5. Overview of the report

Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates

• 2.1. Trends in royalty rates
• 2.2. How do revenue shares figure?
• 2.3. A review of recent literature
• 2.4. Royalty rates in the future

Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals

• 3.1. Partnering agreement structure
• 3.2. Structure of a typical royalty clause
• 3.3. Example royalty clauses
  • 3.3.1. Case study 1
  • 3.3.2. Case study 2
  • 3.3.3. Case study 3
  • 3.3.4. Case study 4

Chapter 4 - Companies actively disclosing royalty rates

• 4.1. Most active companies in disclosing royalty rates

Chapter 5 - Royalty rate contract directory

• Explore royalty rates within the deal contract document to gain greater insight
• Deal Directory
• Deal Directory - Royalty rates in deals - by company A-Z
• Deal Directory - Royalty rates in deals - by therapy area
• Deal Directory - Royalty rates in deals - by stage of development at signing
• Deal Directory - Royalty rates in deals - by technology type
• Royalty rate references
• Example royalty rate deal contract document
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Trends in pharma and biotech royalty rates
• Figure 2: Components of the partnering deal structure
• Figure 3: Components of the partnering royalty clause
• Figure 4: Most active companies disclosing royalty rates
• Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies